Biotech Acquisition Co - Warrants (30/11/2027) OverviewBiotech Acquisition Co - Warrants (30/11/2027)'s EBIT is $-3.7M, above the sector sector average of $-6.4M.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2022
Trailing 12 months ending Sep 30, 2022
As of the most recent data (September 2022), BIOTW shows a EBIT of $-3.7M. That compares with $-1.1M in the prior-year period — down 243.2% year over year. That is above the sector sector average of $-6.4M. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, BIOTW's EBIT is now $-3.7M (was $-1.1M) — a 243.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Biotech Acquisition Co - Warrants (30/11/2027) is outperforming or lagging.
The its sector sector average EBIT is about $-6.4M. Biotech Acquisition Co - Warrants (30/11/2027) is at $-3.7M, which is higher that average. That is roughly 41.6% above the sector mean. Use the comparison chart on this page to see how BIOTW stacks up against individual peers as well.
Tracking BIOTW's ebit over time shows whether Biotech Acquisition Co - Warrants (30/11/2027) is scaling, shrinking, or reshaping that part of the business. The current reading is $-3.7M That compares with $-1.1M in the prior-year period — down 243.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this ebit page, Stockcircle has Biotech Acquisition Co - Warrants (30/11/2027)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-3.7M) with ownership activity and broader fundamentals.
